Rapamycin increases Alzheimer’s-associated plaques in mice, study finds

June 7, 2022

The research also reveals a novel way to decrease the plaques. This is a potential drug target. Contact: Will Sansom, (210) 567-2579, sansom@uthscsa.edu SAN ANTONIO (June 7, 2022) — Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have found that oral administration of rapamycin to an Alzheimer’s […]

Oral pill improves care of patients with bone marrow cancer: Study

June 7, 2022

Results of MOMENTUM myelofibrosis clinical trial presented at ASCO 2022 Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu CHICAGO AND SAN ANTONIO (June 7, 2022) — Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, […]

Faculty surgeon addresses Washington briefing, helps to guide regional trauma response

June 6, 2022

  UT Health San Antonio is an integral partner in the trauma network of San Antonio and South Texas – a national model that involves the military, the Level 1 Trauma Center at University Hospital, trauma faculty of the Joe R. and Teresa Lozano Long School of Medicine, regional hospitals and many other collaborators. Because […]

Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability

June 3, 2022

ERX-41, developed by UT Health San Antonio scientists, exploits a previously unrecognized weakness in breast cancer and other solid tumors. A compound, developed by a team including scientists from The University of Texas Health Science Center at San Antonio, kills a range of hard-to-treat cancer types in petri dishes and animal models by targeting a […]

Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability

June 2, 2022

ERX-41, developed by UT Health San Antonio scientists, exploits a previously unrecognized weakness in breast cancer and other solid tumors. Media contact: Will Sansom, 210-567-2579, Sansom@uthscsa.edu SAN ANTONIO (June 2, 2022) – A compound, developed by a team including scientists from The University of Texas Health Science Center at San Antonio, kills a range of hard-to-treat cancer […]

The massive need for equitable Latino representation in clinical trials

May 31, 2022

Contributed and written by Cliff Despres, Institute for Health Promotion Research Latinos represent less than 10% of volunteers in cancer clinical trials. The lack of Latinos in clinical trials makes it harder for researchers to find treatments tailored for this group — which makes up 18.5% of the U.S. population and a diversity of heritages. This […]